ITM Isotope Technologies Munich and NTP Radioisotopes in South Africa have renewed a long-standing technology transfer and license agreement for the production of the medical radioisotope non-carrier-added lutetium-177 (Lu-177).
Under the agreement, ITM grants NTP the use of intellectual property rights related to the manufacturing of the Lu-177 within the Republic of South Africa and other selected territories, the company said.
In addition, ITM said the two firms have entered a new manufacturing and supply partnership that involves irradiating ytterbium-176 and the SAFARI-1 nuclear reactor operated by Necsa, NTP Radioisotopes' parent company.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.
